CSL Behring’s Hemophilia B Gene Therapy, HEMGENIX®, Shows Sustained Efficacy in Long-Term StudyRyan LongFebruary 7, 2025February 10, 2025 February 7, 2025February 10, 2025 CSL Behring (ASX: CSL, OTCQX: CSLLY) has released four-year data from its Phase 3 HOPE-B trial, demonstrating the long-term efficacy and safety of its gene...
